These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31323533)

  • 1. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review.
    Van der Beek JN; Oosterom N; Pieters R; de Jonge R; van den Heuvel-Eibrink MM; Heil SG
    Crit Rev Oncol Hematol; 2019 Oct; 142():1-8. PubMed ID: 31323533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Dirks NF; Heil SG; de Jonge R; Tissing WJE; Pieters R; van den Heuvel-Eibrink MM; Heijboer AC; Pluijm SMF
    Support Care Cancer; 2019 Jan; 27(1):183-190. PubMed ID: 29922939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Griffioen PH; den Hoed MAH; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    PLoS One; 2018; 13(7):e0199574. PubMed ID: 29985926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
    Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
    BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
    Cheng KK
    Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis.
    Albertioni F; Rask C; Schroeder H; Peterson C
    Anticancer Drugs; 1997 Feb; 8(2):119-24. PubMed ID: 9073308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia.
    Oosterom N; de Jonge R; Smith DEC; Pieters R; Tissing WJE; Fiocco M; van Zelst BD; van den Heuvel-Eibrink MM; Heil SG
    PLoS One; 2019; 14(9):e0221591. PubMed ID: 31527879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Berrevoets M; den Hoed MAH; Zolk O; Hoerning S; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    Pharmacogenet Genomics; 2018 Oct; 28(10):223-229. PubMed ID: 30222710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.
    Gutierrez-Camino A; Oosterom N; den Hoed MAH; Lopez-Lopez E; Martin-Guerrero I; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; Heil SG; García-Orad A; van den Heuvel-Eibrink MM
    Pharmacogenet Genomics; 2017 Aug; 27(8):303-306. PubMed ID: 28628559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
    Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
    Khera S; Kapoor R; Pramanik SK
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis.
    Schmidt E; Thoennissen NH; Rudat A; Bieker R; Schliemann C; Mesters RM; Zühlsdorf M; Müller-Tidow C; Berdel WE
    Ann Oncol; 2008 Sep; 19(9):1644-9. PubMed ID: 18453519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
    den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
    Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?
    Cohen IJ; Wolff JE
    Pediatr Blood Cancer; 2014 Jan; 61(1):7-10. PubMed ID: 24038885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
    Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
    J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.